129 related articles for article (PubMed ID: 34321444)
1. Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations.
Cressey TR; Abbassi M; Lallemant M; Indolfi G; Al-Nahari M; Farid S; Penazzato M; Easterbrook P; El-Sayed MH
Pediatr Infect Dis J; 2021 Dec; 40(12):1081-1086. PubMed ID: 34321444
[TBL] [Abstract][Full Text] [Related]
2. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.
Al-Nahari MM; Abbassi MM; Ebeid FS; Hassany M; El-Sayed MH; Farid SF
Antivir Ther; 2020; 25(2):101-110. PubMed ID: 32367815
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
Younas S; Mukhtar H; Gohar UF; Alsrhani A; Alzahrani B; Junaid K; Qamar MU; Ejaz H
J Infect Dev Ctries; 2021 Oct; 15(10):1489-1496. PubMed ID: 34780372
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
10. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
11. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526
[No Abstract] [Full Text] [Related]
12. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Omar H; El Akel W; Elbaz T; El Kassas M; Elsaeed K; El Shazly H; Said M; Yousif M; Gomaa AA; Nasr A; AbdAllah M; Korany M; Ismail SA; Shaker MK; Doss W; Esmat G; Waked I; El Shazly Y
Aliment Pharmacol Ther; 2018 Feb; 47(3):421-431. PubMed ID: 29193226
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
14. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
15. Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Lin T; Wang X; Gao H; Feng Z; Xu L; Ma J; Li Z; Zhang L; Huang R; Liang X; Liu S
Blood Purif; 2020; 49(6):692-699. PubMed ID: 32289799
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Rivero-Juarez A; Brieva T; Frias M; Rivero A
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Rossotti R; Tavelli A; Bonora S; Cingolani A; Lo Caputo S; Saracino A; Soria A; Marinaro L; Uberti-Foppa C; Mussini C; Puoti M; d'Arminio Monforte A
Dig Liver Dis; 2020 Apr; 52(4):447-451. PubMed ID: 31959479
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
